Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
Pubblicato: 2026-12-01
The Journal of dermatological treatment
Medical Digest Indicizzato: 2026-07-11
This study analyzed the efficacy of switching from IL-23 inhibitors to IL-17 inhibitors in psoriasis patients. Out of 102 patients, 90.2% switched due to insufficient efficacy of IL-23 inhibitors. After 3 months, 82.6% achieved PASI-75, and 66.3% reached an absolute PASI ≤ 1. The overall survival...
Leggi su PubMed